Abstract
The use of intravenous gamma globulin products in both children and adults has increased markedly over the past 5 years, since these agents were licensed in the United States. Product competition has become fierce, with each supplier touting the merits of its own product. A summary of the six products currently available in the United States is presented. Comparisons are made according to method of product manufacture, product specifications, antibody titers, opsonization data, IgG subclass quantification, ease of administration, and side effects.